Effects of Melphalan on Immune Functions in Mice with Plasmacytoma
Author Information
Author(s): I.P. Witzl, B. Ramot, E. Sahar, D. Douer
Primary Institution: Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University
Hypothesis
How does melphalan affect immune and haemopoietic functions in plasmacytoma-bearing mice compared to normal mice?
Conclusion
Melphalan treatment leads to long-term immune deficiencies in plasmacytoma-bearing mice, while normal mice recover their immune functions.
Supporting Evidence
- Melphalan-treated plasmacytoma-bearing mice showed a higher mortality rate than normal mice treated with the same drug.
- Long-term immune deficiencies were observed in T-cell function and IL-2 production in plasmacytoma-bearing mice.
- Normal mice treated with melphalan recovered their immune functions within a year.
Takeaway
This study shows that a medicine called melphalan can hurt the immune system of mice with a type of cancer, even after the cancer is gone.
Methodology
The study involved three groups of BALB/c mice: untreated controls, plasmacytoma-bearing mice treated with melphalan, and normal mice treated with melphalan, followed for one year.
Limitations
The study was conducted on mice, which may not fully represent human responses to melphalan.
Participant Demographics
Female BALB/c mice aged 6-8 weeks were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website